Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
DEA proposes temporary Schedule I placement for three kratom-derived substances, making them illegal to possess or distribute.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmacies, especially those selling kratom products should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective date of temporary order (typically 30 days after Federal Register publication).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Mitragynine pseudoindoxyl, MGM-15, and MGM-16 become Schedule I controlled substances upon temporary order effective date.
Who it affects
All pharmacies, especially those selling kratom products
What you must do
Immediately cease sale, distribution, and possession of these substances; secure and dispose of inventory per DEA guidelines.
Deadline
Effective date of temporary order (typically 30 days after Federal Register publication).
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order